ANAHIT DANIELYAN: Open Payments
NPI 1629007711 · SAINT LOUIS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,296 in 74 payments from 23 companies in 2025. Trend: 2023 $1,887 · 2024 $1,591 · 2025 $1,296
Food & beverage: $1,296
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $221 |
| Novo Nordisk Inc | 12 | $192 |
| AstraZeneca Pharmaceuticals LP | 6 | $148 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $142 |
| Lilly USA, LLC | 5 | $92 |
| Novartis Pharmaceuticals Corporation | 2 | $46 |
| GlaxoSmithKline, LLC. | 2 | $39 |
| BETA BIONICS, INC. | 3 | $37 |
| Axsome Therapeutics, Inc. | 2 | $37 |
| PFIZER INC. | 2 | $36 |
Products named: CAPLYTA, VRAYLAR, Ozempic, Wegovy, AIRSUPRA, UBRELVY, FARXIGA, MOUNJARO.
Industry payments across MO — which companies pay providers there.
